AstraZeneca Pharma India Limited - Laporan Arus Kas (TTM)

AstraZeneca Pharma India Limited
IN ˙ NSEI ˙ INE203A01020
₹ 9,088.15 ↓ -1.55 (-0.02%)
2025-09-05
BAHAGING PRESYO
Laporan Arus Kas (TTM)

Laporan Arus Kas AstraZeneca Pharma India Limited menunjukkan perubahan posisi kas dari waktu ke waktu. Data Laporan Arus Kas meliputi Kas dari Aktivitas Operasional (CFOP), Kas dari Aktivitas Investasi, dan Kas dari Aktivitas Pendanaan.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2021
03-31
2021
09-30
2022
03-31
2022
09-30
2023
03-31
2023
09-30
2024
03-31
2024
09-30
2025
03-31
Cash From Operating Activities 228 1,048 1,550 1,008 856 583 714 279 169 654
Change (%) 359.64 47.89 -34.95 -15.03 -31.94 22.45 -60.95 -39.47 287.43
% of Cash Flow -1,503.02 38.97 92.69 104.91 117.56 112.27 141.51 532.75 -71.48 213.80
Cash From Investing Activities -157 1,730 215 47 118 181 234 217 249 308
Change (%) -1,199.68 -87.56 -77.98 148.08 54.01 29.31 -7.15 14.66 23.55
% of Cash Flow 1,037.42 64.36 12.88 4.93 16.14 34.88 46.43 415.61 -105.64 100.75
Cash From Financing Activities -86 -90 -93 -95 -246 -245 -444 -444 -654 -656
Change (%) 4.56 3.79 1.61 159.56 -0.30 81.19 0.04 47.39 0.29
% of Cash Flow 565.60 -3.34 -5.57 -9.85 -33.70 -47.15 -87.94 -848.22 277.12 -214.56
Cash Flow -15 2,688 1,672 961 729 519 504 52 -236 306
Change (%) -17,825.32 -37.81 -42.53 -24.18 -28.73 -2.85 -89.63 -551.13 -229.53
% of Cash Flow 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00

Source: Capital IQ

Other Listings
IN:506820
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista